Dr. Osipov is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Johns Hopkins Hospital
Sidney Kimmel Comprehensive Cancer Center CRB1 186
Baltimore, MD 21287Phone+1 410-502-4068- Is this information wrong?
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2017 - 2020
Cedars-Sinai Medical CenterResidency, Internal Medicine, 2013 - 2016
Virginia Commonwealth University School of MedicineClass of 2013
Certifications & Licensure
CA State Medical License 2015 - 2025
MD State Medical License 2017 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma Start of enrollment: 2019 Jun 04
- Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma Start of enrollment: 2021 Jul 28
Publications & Presentations
PubMed
- 5-Hydroxymethylcytosine (5-hmC) loss is a marker of malignancy in biliary neoplasms.Gonzalez-Mancera, M., Siref, A., Kosari, K., Nissen, N., Gaddam, S., Hendifar, A., Osipov, A., Waters, K., Hutchings, D., Guindi, M., Larson, B.> ;American Journal of Clinical Pathology. 2024 Feb 12
- 1 citationsNeoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells.Wang, J., Gai, J., Zhang, T., Niu, N., Qi, H., Thomas, D., Li, K., Xia, T., Rodriguez, C., Parkinson, R., Durham, J., McPhaul, T., Narang, A., Anders, R., Osipov, A., ...> ;Science Advances. 2024 Feb 9
- 2 citationsThe Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients.Nikolic, O., Gertych, A., Parker, S., Singh, P., Filippova, D., Dagliyan, G., Ferrone, C., Moore, J., Van Eyk, J., Osipov, A., Hendifar, A., Zheng, L., Tourtellotte, W...> ;Nature Cancer. 2024 Feb 1
- Join now to see all
Press Mentions
Theriva Biologics to Host Key Opinion Leader Webinar on Lead Program, VCN-01 and Advancing Unique Oncolytic Virus TherapeuticsOctober 31st, 2022- Can You Get Two Cancers at the Same Time?October 7th, 2022
- Three-Step Treatment Strategy for Pancreatic CancerJuly 8th, 2022
- Join now to see all
Hospital Affiliations
Cedars-Sinai Medical CenterLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
